Want to see BHC full AI Analyst Report?
Profit Margin by Segment
Shows how much profit each business segment keeps from its sales, revealing where the company has pricing power or cost control and where thin margins could drag overall earnings and cash flow. Highlights which segments can fund growth or debt reduction and which may need efficiency improvements or strategic change.Margin improvement is concentrated in Salix and, episodically, Solta—Salix’s expanding margins reflect stronger Xifaxan demand and commercial leverage, while Solta’s high but volatile margins hide China-driven revenue gains offset by acquisition-related inventory costs. International margins are trending down, consistent with Canadian branded‑generic pressure, and Diversified’s margins have held up via pricing/cost discipline despite declining sales. That mix means near‑term margin momentum is real but fragile: outcomes hinge on Xifaxan exclusivity, successful Solta integration, and exposure to tariffs/340B channel shifts.
Date | Salix | International | Solta Medical | Diversified | Bausch Lomb |
|---|---|---|---|---|---|
Jun 30, 2026 | 80.00 | 30.00 | 52.00 | 65.00 | 24.00 |
Mar 31, 2026 | 73.00 | 31.00 | 44.00 | 61.00 | 22.00 |
Dec 31, 2025 | 76.00 | 26.00 | 40.00 | 70.00 | 28.00 |
Sep 30, 2025 | 80.00 | 31.00 | 50.00 | 71.00 | 23.00 |
Jun 30, 2025 | 73.00 | 28.00 | 42.00 | 63.00 | 19.00 |
Mar 31, 2025 | 68.00 | 32.00 | 47.00 | 62.00 | 16.00 |
Dec 31, 2024 | 73.00 | 35.00 | 53.00 | 69.00 | 24.00 |
Sep 30, 2024 | 68.00 | 36.00 | 47.00 | 70.00 | 24.00 |
Jun 30, 2024 | 68.00 | 31.00 | 46.00 | 66.00 | 23.00 |
Mar 31, 2024 | 66.00 | 33.00 | 45.00 | 56.00 | 22.00 |